All In Biotech

Drug Trial Radar · NCT05363397

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 27, 2023

Primary completion

Feb 1, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
The Florey Institute of Neuroscience and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Neuroscience Trials Australia
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS. Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, TBO-309, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.

Conditions

  • Acute Ischemic Stroke

Interventions

  • TBO-309Drug

    TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with ICH within 24-36 hours of study drug (TBO-309) commencement.Time frame: Within 24-36 hours of initiation of study drug

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Eastern Health- Box Hill Hospital

    Box Hill, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.